EUVIMEDEUVIMED entdecken
Crossref

Omicron breakthrough infections in wild‐type SARS‐CoV‐2 vaccinees elicit high levels of neutralizing antibodies against pangolin coronavirus GX_P2V

Shanshan Lu, Shengdong Luo, Bingke Bai, Zhenping Fan, Bixia Hong, Wen Xu, Hongbin Ma, Weiwei Chen iD, Huahao Fan, Yigang Tong, Lihua Song iD

Journal of Medical Virology · 2023

DOI: 10.1002/jmv.29031 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2023. Verfasst von Shanshan Lu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Advanced Innovation Center for Soft Matter Science and Engineering, College of Life Science and Technology, Beijing University of Chemical Te…. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Omicron BF.7 became the predominant SARS‐CoV‐2 variant in Beijing after the abolishment of Zero‐COVID policy in December 2022. The ability of antibodies elicited by BF.7 infection to cross‐react with SARS‐CoV‐2‐like viruses is unknown. This study aimed to investigate the cross‐reactive neutralizing antibodies against SARS‐CoV‐2‐related pangolin coronavirus GX_P2V in sera from vaccinated and/or SARS‐CoV‐2‐infected individuals. All vaccinated individuals who recovered from Omicron BF.7 breakthrough infections exhibited substantially higher levels of neutralizing antibodies against GX_P2V, compared to other subject groups, with a geometric mean titer (GMT) of 362. Uninfected individuals who received four‐mixed‐dose vaccines also demonstrated higher levels of neutralizing antibodies (GMT = 44) against GX_P2V than those uninfected individuals who received two‐ or three‐dose vaccines and those unvaccinated convalescents of wild‐type SARS‐CoV‐2. This study highlights the significance of prior vaccinations with wild‐type SARS‐CoV‐2 vaccines in generating potent cross‐protective immunity against future spillovers of SARS‐CoV‐2‐like viruses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19HumansAnimalsAntibodies, NeutralizingPangolinsBreakthrough InfectionsCOVID-19 VaccinesAntibodies, Viral

Stichwörter der Autor:innen

COVID-19Omicron BF.7cross-protective immunitypangolin coronavirus GX_P2V

Substanzen

Antibodies, NeutralizingCOVID-19 VaccinesAntibodies, Viral

Autor:innen und Institutionen

  • Beijing Advanced Innovation Center for Soft Matter Science and Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China.
  • Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.

ORCID-Profile: Weiwei Chen, Lihua Song

Zitieren

APA

Lu, S., Luo, S., Bai, B., Fan, Z., Hong, B., Xu, W., Ma, H., Chen, W., Fan, H., Tong, Y., & Song, L. (2023). Omicron breakthrough infections in wild‐type SARS‐CoV‐2 vaccinees elicit high levels of neutralizing antibodies against pangolin coronavirus GX_P2V. Journal of Medical Virology. https://doi.org/10.1002/jmv.29031

Vancouver

Lu S, Luo S, Bai B, Fan Z, Hong B, Xu W, et al. Omicron breakthrough infections in wild‐type SARS‐CoV‐2 vaccinees elicit high levels of neutralizing antibodies against pangolin coronavirus GX_P2V. Journal of Medical Virology. 2023. doi:10.1002/jmv.29031

BibTeX
@article{Lu2023,
  author = {Lu, Shanshan and Luo, Shengdong and Bai, Bingke and Fan, Zhenping and Hong, Bixia and Xu, Wen and Ma, Hongbin and Chen, Weiwei and Fan, Huahao and Tong, Yigang and Song, Lihua},
  title = {Omicron breakthrough infections in wild‐type SARS‐CoV‐2 vaccinees elicit high levels of neutralizing antibodies against pangolin coronavirus GX_P2V},
  journal = {Journal of Medical Virology},
  year = {2023},
  doi = {10.1002/jmv.29031}
}
Kostenlos starten →